Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
23.78
-0.64 (-2.62%)
May 14, 2025, 1:20 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Biopharmaceutical and Diagnostic Solutions | 933.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Growth | 6.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering | 170.29M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Growth | -17.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Biopharmaceutical and Diagnostic Solutions Operating Profit | 165.64M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Operating Profit Growth | -11.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Operating Profit | 33.10M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Operating Profit Growth | -38.27% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Operating Profit | -37.59M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Operating Profit Growth | -7.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Biopharmaceutical and Diagnostic Solutions Gross Profit | 268.78M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharmaceutical and Diagnostic Solutions Gross Profit Growth | -0.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Gross Profit | 56.17M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Engineering Gross Profit Growth | -6.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Gross Profit | -22.63M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Gross Profit Growth | 26.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| EMEA | 667.83M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | 5.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC | 96.24M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Growth | -6.48% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America | 308.95M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| North America Growth | -2.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South America | 31.02M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| South America Growth | 0.50% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Backlog | 853.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Backlog Growth | -9.73% |
Log In |
Log In |
Log In |
Log In | Upgrade
|